Akari Therapeutics, a biotechnology company specializing in advanced therapies for autoimmune and inflammatory diseases, has announced the appointment of Samir R. Patel, M.D. to its Board of Directors. Dr. Patel, an experienced life sciences entrepreneur, brings extensive experience and a successful track record in the field. His appointment comes as the company seeks to further advance its lead asset, nomacopan.
Dr. Patel currently serves as the founder and principal of PranaBio Investments, providing consulting, strategic advisory, and investment services for small cap biotechnology companies. He has over 20 years of experience in the life sciences sector, including co-founding successful startups and holding multiple roles in Medical Affairs with Centocor, Inc. In addition to his entrepreneurial endeavors, Dr. Patel is a consultant to GE Global Research, focusing on biotechnological innovation.
Akari Therapeutics is currently developing nomacopan, a bispecific recombinant inhibitor, for the treatment of autoimmune and inflammatory diseases. The company’s pipeline includes a Phase 3 clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), as well as research on nomacopan for adult HSCT-TMA and geographic atrophy. Akari has received various designations, including Orphan Drug and Rare Pediatric Disease, for its innovative therapy.
The appointment of Dr. Patel to Akari’s Board of Directors signals the company’s commitment to advancing its lead asset and realizing its full potential in the biotechnology industry. With Dr. Patel’s expertise and experience, Akari Therapeutics aims to further develop and introduce innovative therapies for autoimmune and inflammatory diseases.
